Prosigna Breast Cancer Assay Now Approved for Reimbursement in Germany

Prognostic Information


Accurately determine risk of recurrence with Prosigna

Prosigna Scores correlate with 10-year probability of distant recurrence.

  • The Prosigna Scores for a cohort of postmenopausal women with hormone receptor-positive, early-stage breast cancer were compared to distant recurrence-free survival (DRFS) following surgery and treatment with 5 years of adjuvant endocrine therapy followed by 5 years of observation (see Data Summary).
  • This study resulted in a model relating the Prosigna Score to the probability of distant recurrence in 2 tested patient populations (node negative and node positive), including a 95% confidence interval.

Reference: 1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013.

Prosigna is indicated for in vitro diagnostic use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy for assessment of risk of distant recurrence of disease.